These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 36601737)

  • 1. Itacitinib Population Pharmacokinetics and Exposure-Response in Patients With Acute Graft-Versus-Host Disease.
    Chen X; Xun Z; Yuska B; McGee R; Yeleswaram S
    J Clin Pharmacol; 2023 May; 63(5):622-632. PubMed ID: 36601737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial.
    Zeiser R; Socié G; Schroeder MA; Abhyankar S; Vaz CP; Kwon M; Clausen J; Volodin L; Giebel S; Chacon MJ; Meyers G; Ghosh M; Deeren D; Sanz J; Morariu-Zamfir R; Arbushites M; Lakshminarayanan M; Barbour AM; Chen YB
    Lancet Haematol; 2022 Jan; 9(1):e14-e25. PubMed ID: 34971577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease.
    Schroeder MA; Khoury HJ; Jagasia M; Ali H; Schiller GJ; Staser K; Choi J; Gehrs L; Arbushites MC; Yan Y; Langmuir P; Srinivas N; Pratta M; Perales MA; Chen YB; Meyers G; DiPersio JF
    Blood Adv; 2020 Apr; 4(8):1656-1669. PubMed ID: 32324888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A biomarker signature to predict complete response to itacitinib and corticosteroids in acute graft-versus-host disease.
    Pratta M; Paczesny S; Socie G; Barkey N; Liu H; Owens S; Arbushites MC; Schroeder MA; Howell MD
    Br J Haematol; 2022 Aug; 198(4):729-739. PubMed ID: 35689489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Itraconazole or Rifampin on Itacitinib Pharmacokinetics When Administered Orally in Healthy Subjects.
    Barbour AM; Punwani N; Epstein N; Landman R; Cimino E; Yuska B; Wang P; He K; Chen X; Yeleswaram S
    J Clin Pharmacol; 2019 Dec; 59(12):1641-1647. PubMed ID: 31282592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effect of Renal Impairment on the Pharmacokinetics and Safety of Itacitinib.
    Srinivas N; Barbour AM; Epstein N; Zhou G; Petusky S; Xun Z; Yuska B; Marbury T; Chen X; Yeleswaram S; Punwani N
    J Clin Pharmacol; 2020 Aug; 60(8):1022-1029. PubMed ID: 32149388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Clinical Cardiac Safety of Itacitinib, a JAK1 Inhibitor, in Healthy Participants.
    Gong X; Darpo B; Xue H; Punwani N; He K; Barbour AM; Epstein N; Landman R; Chen X; Yeleswaram S
    Clin Pharmacol Drug Dev; 2020 Aug; 9(6):677-688. PubMed ID: 31821750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Hepatic Impairment on the Pharmacokinetics of Itacitinib.
    Barbour AM; Rockich K; Cimino E; Zhou G; Leonetti-Whalen C; Chen X; Yeleswaram S; Epstein N; Punwani N
    J Clin Pharmacol; 2021 Jul; 61(7):954-960. PubMed ID: 33434286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetic and Exposure-Safety Analyses of Ibrutinib for the Treatment of Chronic Graft-Versus-Host Disease.
    Ogawa T; Mita S; Atluri H; Iwaki Y
    J Clin Pharmacol; 2023 May; 63(5):613-621. PubMed ID: 36597869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases.
    Covington M; He X; Scuron M; Li J; Collins R; Juvekar A; Shin N; Favata M; Gallagher K; Sarah S; Xue CB; Peel M; Burke K; Oliver J; Fay B; Yao W; Huang T; Scherle P; Diamond S; Newton R; Zhang Y; Smith P
    Eur J Pharmacol; 2020 Oct; 885():173505. PubMed ID: 32861662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study.
    Naing A; Powderly JD; Nemunaitis JJ; Luke JJ; Mansfield AS; Messersmith WA; Sahebjam S; LoRusso PM; Garrido-Laguna I; Leopold L; Geschwindt R; Ding K; Smith M; Berlin JD
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective treatment of low-risk acute GVHD with itacitinib monotherapy.
    Etra A; Capellini A; Alousi A; Al Malki MM; Choe H; DeFilipp Z; Hogan WJ; Kitko CL; Ayuk F; Baez J; Gandhi I; Kasikis S; Gleich S; Hexner E; Hoepting M; Kapoor U; Kowalyk S; Kwon D; Langston A; Mielcarek M; Morales G; Özbek U; Qayed M; Reshef R; Rösler W; Spyrou N; Young R; Chen YB; Ferrara JLM; Levine JE
    Blood; 2023 Feb; 141(5):481-489. PubMed ID: 36095841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ruxolitinib exposure in patients with acute and chronic graft versus host disease in routine clinical practice-a prospective single-center trial.
    Isberner N; Kraus S; Grigoleit GU; Aghai F; Kurlbaum M; Zimmermann S; Klinker H; Scherf-Clavel O
    Cancer Chemother Pharmacol; 2021 Dec; 88(6):973-983. PubMed ID: 34505930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs.
    Nomoto M; Zamora CA; Schuck E; Boyd P; Chang MK; Aluri J; Siu YA; Lai WG; Yasuda S; Ferry J; Rege B
    Br J Clin Pharmacol; 2018 May; 84(5):952-960. PubMed ID: 29341245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies.
    Zeidan AM; Cook RJ; Bordoni R; Berenson JR; Edenfield WJ; Mohan S; Zhou G; Asatiani E; Srinivas N; Savona MR
    Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):523-534. PubMed ID: 35260349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pooled Population Pharmacokinetic Analyses of Venetoclax in Patients Across Indications and Healthy Subjects from Phase 1, 2, and 3 Clinical Trials.
    Gong JQX; Suleiman AA; Menon R; Deng R; Mensing S; Salem AH
    J Clin Pharmacol; 2023 Aug; 63(8):950-960. PubMed ID: 37055934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation.
    Benkali K; Rostaing L; Premaud A; Woillard JB; Saint-Marcoux F; Urien S; Kamar N; Marquet P; Rousseau A
    Clin Pharmacokinet; 2010 Oct; 49(10):683-92. PubMed ID: 20818834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
    Keam SJ; Keating GM
    Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.